Policy making on data exclusivity in the european union: From industrial interests to legal realities

Journal of Health Politics, Policy and Law

Volumn 34, Issue 6, 2009, Pages 979-1010

  Adamini, Sandra ^a   Maarse, Hans ^b   Versluis, Esther ^b   Light, Donald W ^c  

^a ECORYS Netherlands   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; EUROPEAN UNION; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; PATENTS AS TOPIC; POLICY MAKING; POLITICS;

EID: 73249143524     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-2009-033     Document Type: Review

References (60)

1. Abbott, F. M. 2004. The Doha Declaration on the TRIPS Agreement and Public Health and the Contradictory Trend in Bilateral and Regional Free Trade Agreements. Occasional paper 14. Geneva: Friends World Committee for Consultation.
2. Angell, M. 2005. The Truth about the Drug Companies: How They deceive Us and What to Do about It. New York: Random House Trade.
3. Boessen, S. 2008. The Politics of European Union Health Policy-Making: An Actor-Centred Institutionalist Analysis. Maastricht, Netherlands: Universitaire Pers Maastricht.
4. CMS Cameron McKenna and Andersen Consulting. 2000. Evaluation of the Operation of Community Procedures for the Authorisation of Medicinal Products. Evaluation carried out on behalf of the European Commission. Brussels: European Commission, DG Enterprise.
5. Commission of the European Communities (CEC). 1998. The Single Market in Pharmaceuticals. Communication from the Commission. COM (98) 588 final. Brussels: CEC.
6. -. 2001a. Proposal for a Regulation of the European Parliament and of the Council Laying Down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Agency for the Evaluation of Medicinal Products and Proposal for a Directive of the European Parliament and of the Council Amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. COM (2001) 404 final. Brussels: CEC.
7. -. 2001b. Report from the Commission on the Experience Acquired as a Result of the Operation of the Procedures for Granting Marketing Authorisations for Medicinal Products. Brussels: CEC.
8. -. 2003. Partnership and Co-Operation Agreement between the European Communities and Their Member States, and Ukraine. www.trade.ec.europa.eu/doclib/ docs/2003/october/tradoc-111612.pdf (accessed August 24, 2009).
9. -. 2004. Agreement Establishing an Association between the European Community and Its Member States, of the One Part, and the Republic of Chile, of the Other Part. EU-Chile Free Trade Agreement. Article 168. www.trade.ec.europa. eu/ doclib/docs/2004/november/tradoc-111620.pdf (accessed August 24, 2009).
10. -. 2008. Pharmaceutical Sector Inquiry: Preliminary Report of DG Competition. Staff working paper, November 28. Brussels: CEC.
11. Correa, C. M. 2006. Protecting Test Data for Pharmaceutical and Agrochemical Products under Free Trade Agreements. In Negotiating Health: Intellectual Property and Access to Medicines, ed. P. Roffe, G. Tansey, and D. Vivas-Eugui, 81-96. London: Earthscan.
12. Council of the European Communities. 1987a. Council Directive 87/21/EEC of 22 December 1986 Amending Directive 65/65/EEC on the Approximation of Provisions Laid Down by Law, Regulation or Administrative Action Relating to Proprietary Medicinal Products. Official Journal of the European Union (L15, January 17): 36-37.
13. -. 1987b. Council Directive 87/22/EEC of 22 December 1986 on the Approximation of National Measures Relating to the Placing on the Market of High-Technology Medicinal Products, Particularly Those Derived from Biotechnology. Official Journal of the European Union (L015, January 17): 38-41.
14. -. 1993. Council Regulation (EEC) No 2309/93 of 22 July 1993 Laying Down Community Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Agency for the Evaluation of Medicinal Products. Official Journal of the European Union (L214, August 24): 1.
15. -. 2004. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 Amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. Official Journal of the European Union (L136, April 30): 34-57.
16. Dodds-Smith, I. 2000. Data Protection and Abridged Applications for Marketing Authorisations in the Pharmaceutical Industry. In Pharmaceutical Medicine, Biotechnology, and European Law, ed. R. Goldberg and J. Lonbay, 93-136. Cambridge: Cambridge University Press.
17. Eastern Europe Powers the EC Regulatory Convoy. 2000. Scrip, December 6, 8.
18. EC Reforms Balanced, Says Industry. 2001. Scrip, July 25, 2.
19. Editorial: A Free Hand. 2002. Revue Prescrire 22 (229): 401.
20. European Federation of Pharmaceutical Industries and Associations (EFPIA). 1999. Regulation 2000: An EFPIA Perspective on the Future of Medicines' Regulation in Europe. April. Brussels: EFPIA.
21. European Generic Medicines Association (EGA). 2000. Data Exclusivity: A Major Obstacle to Innovation and Competition in the EU Pharmaceutical Sector. Brussels: EGA.
22. European Parliament. 2002a. Debates: Tuesday, 22 October 2002-Strasbourg. Plenary debate. www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT +CRE+20021022+ITEM-001+DOC+XML+V0//EN&language=EN.
23. -. 2002b. Report on the Proposal for a Directive of the European Parliament and of the Council Amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use - Committee on the Environment, Public Health, and Consumer Policy. October 9.
24. European Parliament and Council. 2001. Directive 2001/83 of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. Official Journal of the European Union (L311, November 28): 67-128.
25. Feick, J. 2005. Learning and Interest Accommodation in Policy and Institutional Change: EC Risk Regulation in the Pharmaceuticals Sector. London: Centre for Analysis of Risk and Regulation.
26. Feick, J., and A. Broscheid. 2005. A Great Leap Ahead or an Incremental Step? The 2001-2004 Review of European Pharmaceuticals Authorization and Regulatory Europeanization. Cologne: Max Planck Institute for the Study of Societies.
27. Gambardella, A., L. Orsenigo, and F. Pammolli. 2000. Global Competitiveness in Pharmaceuticals: A European Perspective. Brussels: European Commission.
28. Garattini, S., V. Bertele, and L. Li Bassi. 2003. Light and Shade in Proposed Revision of EU Drug-Regulatory Legislation. Lancet 361:635-636.
29. Golub, J. 1996. State Power and Institutional Influence in European Integration: Lessons from the Packaging Waste Directive. Journal of Common Market Studies 34 (3): 313-339.
30. Grabowski, H. 2007. Data Exclusivity for New Biological Entities. Working paper, June. Durham, NC: Duke University Department of Economics. www.econ.duke .edu/Papers/PDF/DataExclusivityWorkingPaper.pdf (accessed August 24, 2009).
31. Greenwood, J. 2003. Interest Representation in the European Union. Hampshire, U.K.: Palgrave Macmillan.
32. Health GAP (Global Access Project). 2003. The Central America Free Trade Agreement, Access to AIDS Medicines, and Intellectual Property. Fact sheet. New York: Health GAP.
33. Héritier, A. 1999. Policy-Making and Diversity in Europe: Escape from Deadlock. Cambridge: Cambridge University Press.
34. IMS Health. 2001. Data Exclusivity: The Generics Market's Third Hurdle. November. Quoted in Pugatch 2004: 13.
35. Keyhani, S., M. Diener-West, and N. Powe. 2006. Are Development Times for Pharmaceuticals Increasing or Decreasing? Health Affairs 25:461-468.
36. Kingham, R. F., and G. H. Castle. 2000. Data and Market Exclusivity for Pharmaceuticals in the European Community. Food and Drug Law Journal 55 (2): 209-223.
37. Levine, M. E., and J. L. Forrence. 1990. Regulatory Capture, Public Interest, and the Public Agenda: Toward a Synthesis. Journal of Law, Economics, and Organization 6:167-198.
38. Light, D. W. 2007. Misleading Congress on Drug Development. Journal of Health Politics, Policy and Law 32:895-913.
39. Light, D. W., and R. N. Warburton. 2005. Extraordinary Claims Require Extraordinary Evidence. Journal of Health Economics 24:1030-1033.
40. Love, J. P. 1997. Health Registration Data Exclusivity, Biomedical Research, and Restrictions on the Introduction of Generic Drugs. Statement before U.S. Senate, Subcommittee on Labor, Health, and Human Services and Education and Related Agencies Committee on Appropriations. 105th Cong., 1st sess., October 21. www .cptech.org/pharm/senhregd.html.
41. Majone, G. 1996. Regulating Europe. London: Routledge.
42. Mazey, S., and J. Richardson. 2006. Interest Groups and EU Policy-making: Organisational Logic and Venue Shopping. In European Union: Power and Policy-making, 3rd. ed., ed. J. Richardson, 247-268. New York: Routledge.
43. Medawar, C., and H. Hardon. 2004. Medicines Out of Control? Antidepressants and the Conspiracy of Goodwill. Amsterdam: Aksant Academic Publishers.
44. Médecins sans Frontières. 2003. Trading Away Health: Intellectual Property and Access to Medicines in the Free Trade Area of the Americas (FTAA) Agreement. Paris: Médecins sans Frontières.
45. Medicines in Europe Forum. 2003. "Data Protection" = Protection of Clinical Trial Results. Prescrire, October 15.
46. Ministers of Health of the Acceding Countries. 2003. The Acceding Countries Declaration (Milan Declaration), signed September 5, Milan. www.egagenerics.com/ doc/milandec.pdf.
47. National Economic Research Associates (NERA). 1998. Policy Relating to Generic Medicines in the OECD. London: NERA.
48. Neuhold, C. 2001. The "Legislative Backbone" Keeping the Institution Upright? The Role of European Parliament Committees in the EU Policy-Making Process. European Integration online Papers (EIoP) 5 (10): 1-21.
49. Nugent, N. 2003. The Government and Politics of the European Union. New York: Palgrave Macmillan.
50. Permanand, G. 2006. EU Pharmaceutical Regulation: The Politics of Policy-Making. Manchester: Manchester University Press
51. . Perry, G. 2000. EU and Health Registration Data. Letter of January 27 to E-Drug (Essential Drugs) listserv. www.essentialdrugs.org/edrug/archive/ 200001/msg00094.php.
52. Peterson, J., and E. Bomberg. 1999. Decision-Making in the European Union. Hampshire, U.K.: Palgrave.
53. Pugatch, M. 2004. Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access. Geneva: International Centre for Trade and Sustainable Development.
54. -. 2006. Intellectual Property, Data Exclusivity, Innovation, and Market Access. In Negotiating Health: Intellectual Property and Access to Medicines, ed. P. Roffe, G. Tansey, and D. Vivas-Eugui, 97-132. London: Earthscan.
55. Reichman, J. H. 2006. The International Legal Status of Undisclosed Clinical Trials Data: From Private to Public Goods? In Negotiating Health: Intellectual Property and Access to Medicines, ed. P. Roffe, G. Tansey, and D. Vivas-Eugui, 133-150. London: Earthscan.
56. Sanjuan Rius, J. 2006. U.S. and EU Protection of Pharmaceutical Test Data. Consumer Project on Technology (CPTech) discussion paper no. 1. April 12. Washington, D.C.: CPTech. www.cptech.org/publications/CPTechDPNo1TestData.pdf.
57. Scharpf, F. W. 1997. Games Real Actors Play: Actor-Centered Institutionalism in Policy Research. Oxford: Westview Press.
58. -. 2000. Institutions in Comparative Policy Research. Comparative Political Studies 33 (6-7): 762-790.
59. -. 2006. The Joint-Decision Trap Revisited. Journal of Common Market Studies 44 (4): 845-864.
60. Stolk, P., and D. W. Light. 2008. Did the U.S. Eclipse European Pharmaceutical Research Productivity? An Analysis of Major Reports as Searchlights in the Fog. Escher Project, Department of Pharmacoepidemiology. Utrecht: University of Utrecht.